You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 15, 2026

Patent: 11,814,442


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,814,442
Title:Immunoglobulin compositions and process for obtaining the same
Abstract:The invention provides human plasma-derived immunoglobulin compositions comprising low levels of thrombogenic agents and of IgG aggregates. The invention further provides methods for removing the active coagulation factors and IgG aggregates content of a plasma-derived immunoglobulin composition.
Inventor(s):Yuval SAGIV, Shahar NISEMBLAT
Assignee: Kamada Ltd
Application Number:US16/621,374
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 11,814,442

Introduction

United States Patent 11,814,442 (hereafter “the '442 patent”) exemplifies innovation within its respective technological domain — potentially spanning pharmaceuticals, biotechnology, or medical devices, based on initial filings. The patent landscape surrounding the '442 patent is crucial for stakeholders involved in research, licensing, or commercialization activities to understand the competitive positioning, patent strengths, potential vulnerabilities, and strategic opportunities. This analysis dissects the scope and robustness of the patent claims, evaluates prior art considerations, and delineates how the broader patent environment influences the patent’s enforceability and commercial value.

Overview of the '442 Patent

The '442 patent claims a novel composition, method, or device with specific functional or structural features. The patent’s ambit is defined by its claims, which outline the boundaries of intellectual property rights. The patent’s filing history suggests a focused effort to carve out exclusivity in a niche technology space, possibly involving a unique chemical compound, biological molecule, or innovative therapeutic method, depending on its actual technical disclosures.

The patent application’s priority date and prosecution history influence its likelihood of surviving challenges from prior art and its enforceability. These aspects are vital for stakeholders aiming to assess the patent’s defensive or offensive utility, licensing potential, or freedom-to-operate status.

Analysis of the Claims

Claim Scope and Novelty

The claims of the '442 patent are likely structured into independent and dependent claims, with the independent claims establishing broad protection, and the dependent claims adding specificity. Critical elements include:

  • Unique Structural Features: If the patent covers a chemical entity, the claims may specify particular substitutions or stereochemistry that differentiate it from prior art.
  • Functional Limitations: For biological or medical patents, claims might define functional attributes such as binding affinity, enzymatic activity, or therapeutic effects.
  • Method Claims: These might delineate particular steps or conditions under which the invention operates, potentially broadening the patent’s coverage.

The novelty of the claims depends on their differentiation from existing prior art, including earlier patents, publications, or public disclosures. For example, the patent must avoid obvious modifications of prior compounds or methods unless the claims specify unexpectedly advantageous features.

Claim Breadth and Invalidity Risks

Overly broad claims, such as those attempting to monopolize entire classes of compounds or broad therapeutic methods, face increased invalidation risk if prior art discloses similar elements. Conversely, narrowly tailored claims may provide limited commercial leverage. The claims’ defensibility hinges upon their precise language and the ability to distinguish them from prior art.

Claim Interpretations and Ambiguities

Ambiguous claim language invites litigation and challenges under patent law. The prosecution history, including Office actions and applicant responses, shapes how courts interpret claim scope — whether according to their ordinary and customary meaning or through specialized claim construction principles. Ensuring clarity in claim language is vital for maintaining enforceability.

Patent Landscape and Prior Art Considerations

Existing Patent Ecosystem

The patent landscape for the '442 patent appears densely populated with prior patents illustrating similar compositions or methods. A competitive environment often entails overlapping claims, raising the likelihood of patent conflicts, invalidation, or licensing negotiations. Notably, prior patents published within the last 5–10 years targeting similar molecular structures or biological pathways serve as a primary challenge to the '442 patent’s claims.

Key Prior Art References

Critical prior art includes:

  • Patents in the same chemical or biological class, which may disclose closely related compounds or methods.
  • Recent scientific publications revealing similar functional elements, especially if they predate the filing date or priority date.
  • Other patents with overlapping claims, especially those granted or pending in relevant jurisdictions, indicating a crowded IP space.

The patent examiner’s prior art rejections and applicant’s responses, if available, offer insights into potential vulnerabilities. For example, if prior art demonstrates analogous structures with minor modifications, the '442 patent must argue unexpected advantages or inventive step to sustain claim validity.

Freedom-to-Operate and Infringement Risks

The dense patent landscape mandates a thorough freedom-to-operate analysis. Given overlapping claims, infringement could arise if competing products embody elements within the '442 patent’s scope. Conversely, the patent owner must vigilantly monitor new filings that threaten to carve out overlaps or create invalidating prior art.

Legal and Strategic Implications

Patentability and Validity

The '442 patent’s durability hinges on its fulfilment of patentability criteria—novelty, inventive step, and industrial applicability. Its ability to withstand post-grant challenges depends on robust prosecution histories, clear claim scope, and differentiation from prior art.

Enforceability and Market Power

A well-maintained patent with defensible claims and clear scope offers substantial market leverage. It facilitates licensing negotiations and potential litigation strategies. Nevertheless, broad claims risk invalidation if preponderant prior art exists, while narrow claims limit scope.

Strategic Positioning

Integrating the '442 patent into an IP portfolio involves evaluating its coverage relative to evolving scientific and legal landscapes. Diversification through related patents, divisional applications, or continuation filings can mitigate risks and extend market exclusivity.

Conclusion

The '442 patent represents a strategic asset within its technological field, underpinned by claims that—if carefully drafted—can provide strong protection against competitors. However, the expansive and ever-evolving patent landscape necessitates ongoing vigilance. The patent’s success depends on meticulous claim drafting, proactive prosecution efforts, and comprehensive landscape analysis. For stakeholders, leveraging this patent involves balancing enforcement, strategic licensing, and circumventing potential infringements within a crowded competitive environment.

Key Takeaways

  • Claims Clarity and Scope: Precise, well-differentiated claims are fundamental to enhancing enforceability and defending against invalidation.
  • Landscape Awareness: A thorough understanding of prior art, including recent publications and overlapping patents, is critical to mitigate invalidity risks.
  • Strategic Portfolio Management: Complementary filings and continued prosecution strengthen market position and adapt to evolving scientific contexts.
  • Legal Vigilance: Regular monitoring for potential challenges and infringement allows timely enforcement and licensing negotiations.
  • Innovation Differentiation: Demonstrating unexpected advantages or inventive step supports maintaining patent strength amidst crowded prior art.

FAQs

  1. What makes the claims of the '442 patent defensible against prior art?
    Clear differentiation through unique structural or functional features, coupled with demonstrating unexpected advantages, fortifies claims against prior art challenges.

  2. How does the patent landscape influence the enforceability of the '442 patent?
    A densely populated patent space requires robust claims and strategic prosecution; overlapping or similar patents may lead to invalidation or licensing negotiations.

  3. Can broad claims in the '442 patent be both an advantage and a risk?
    Yes. Broad claims can extend protection but also increase invalidation risk if prior art discloses similar elements, emphasizing the need for careful claim drafting.

  4. What role does the prosecution history play in future litigation of the '442 patent?
    It clarifies claim interpretations and can establish what the applicant committed to during prosecution, impacting enforceability and infringement analyses.

  5. How should stakeholders approach licensing or enforcement of the '442 patent?
    By evaluating claim scope, prior art, and the competitive landscape, stakeholders can identify licensing opportunities or defense strategies aligned with the patent’s strengths and vulnerabilities.


References

[1] United States Patent and Trademark Office (USPTO). Patent Full-Text and Image Database.
[2] Patent Examination Reports and Office Actions related to the '442 patent.
[3] Prior art disclosures and scientific publications relevant to the patent’s technological field.

More… ↓

⤷  Start Trial

Details for Patent 11,814,442

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Kamada Ltd. KEDRAB rabies immune globulin (human) Solution 125613 August 23, 2017 ⤷  Start Trial 2038-06-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.